![]() ![]() Various statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. ![]() This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. The information that Checkmate Pharmaceuticals posts on these channels and websites could be deemed to be material information. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. Investors and others should note that we communicate with our investors and the public using our website ( our investor relations website (ir.), and on social media (Twitter and LinkedIn), including but not limited to: investor presentations and investor fact sheets, U.S. ![]() Information regarding Checkmate Pharmaceuticals is available at Availability of Other Information About Checkmate Pharmaceuticals Checkmate Pharmaceuticals’ product candidate, vidutolimod (CMP-001), is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the body’s innate immune system to attack tumors in combination with other therapies. This increase was primarily attributable to increases in personnel and operating expense incurred in connection with Checkmate operating as a publicly traded company.Ĭash, cash equivalents and investments: Cash, cash equivalents and available-for-sale investments were $111.5 million as of March 31, 2021.Ĭheckmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. General and administration expenses (G&A): G&A expenses for the first quarter of 2021 were $3.8 million, compared to $1.5 million for the same period in the prior year. This increase reflected a milestone payment of $2.0 million in the first quarter of 2021 triggered by initiation of patient dosing in our Phase 2, first-line melanoma trial, as well as increases in personnel and operating expense for the planning and initiation of additional clinical trials with vidutolimod. Research and development expenses (R&D): R&D expenses for the first quarter of 2021 were $10.4 million, compared to $6.3 million for the same period in the prior year. #CHECKMATE PHARMACEUTICALS TRIAL#The companies will collaborate on a Phase 2, proof of concept, multi-indication trial with patient cohorts in anti-PD-1 naïve and anti-PD-1 refractory cutaneous squamous cell carcinoma and anti-PD-1 refractory Merkel cell carcinoma. #CHECKMATE PHARMACEUTICALS SKIN#In May, Checkmate announced the planned expansion of the development program for vidutolimod into non-melanoma skin cancers supported by a clinical supply agreement with Regeneron to evaluate the combination of vidutolimod and Libtayo® (cemiplimab). New translational data were presented from our Phase 1b trial of vidutolimod in combination with pembrolizumab in patients with melanoma refractory to PD-1 blockade at the 2021 American Association for Cancer (AACR) Annual Meeting.Ĭollaboration and New Indication Expansion Initial data in a subset of patients are expected before the end of 2021. Both melanoma trials are supported by a clinical collaboration with Bristol Myers Squibb.Ī Phase 2 trial of vidutolimod in combination with pembrolizumab in recurrent or metastatic squamous cell head and neck cancer. nivolumab monotherapy in first-line metastatic or unresectable melanoma.Ī Phase 2 trial of vidutolimod in combination with nivolumab in anti-PD-1 refractory advanced melanoma. Year to date, Checkmate has initiated patient dosing across all three of our core clinical trials evaluating vidutolimod.Ī randomized Phase 2/3 trial of vidutolimod in combination with nivolumab vs. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |